Dissolve-E: AWMF Guideline Registry
0.2.0 - ci-build

Dissolve-E: AWMF Guideline Registry - Local Development build (v0.2.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 DISSOLVE-E Implementation Guide
... 2 Profiles
... 3 Extensions
... 4 Code Systems
... 5 Value Sets
... 6 Downloads
... 7 Examples
... 8 Artifacts Summary
.... 8.1 AWMF Member Organization
.... 8.2 AWMF S1 Guideline Registry Record
.... 8.3 AWMF S2e Guideline Registry Record
.... 8.4 AWMF S2k Guideline Registry Record
.... 8.5 AWMF S3 Guideline Registry Record
.... 8.6 Citation List
.... 8.7 Conceptual Cohort Definition Comparator
.... 8.8 Conceptual Cohort Definition Intervention
.... 8.9 Conceptual Cohort Definition Outcome
.... 8.10 Conceptual Cohort Definition Population
.... 8.11 Evidence Assessment
.... 8.12 Evidence Internal Assessment AGREE II
.... 8.13 Evidence Internal Assessment AMSTAR 2
.... 8.14 Evidence Internal Assessment Cochrane Risk of Bias
.... 8.15 Evidence Internal Assessment ROBIS
.... 8.16 Evidence Internal Validity Assessment
.... 8.17 Evidence Overall Assessment GRADE
.... 8.18 Evidence Overall Assessment Oxford 2011
.... 8.19 Evidence Overall Quality Assessment
.... 8.20 Evidence Report with Contact Slices
.... 8.21 Guideline
.... 8.22 Guideline Attachment
.... 8.23 Guideline Author
.... 8.24 Guideline Author Role
.... 8.25 Guideline Registry Record
.... 8.26 Medical Society
.... 8.27 Outcome Evidence
.... 8.28 Patient Organization
.... 8.29 PICO Question
.... 8.30 Recommendation
.... 8.31 Recommendation Justification
.... 8.32 Recommendation Justification AWMF
.... 8.33 Recommendation Justification Expert Consensus
.... 8.34 Recommendation Justification GRADE
.... 8.35 Recommendation Justification OXFORD 2009
.... 8.36 Recommendation Justification OXFORD 2011
.... 8.37 Recommendation Justification SIGN
.... 8.38 Artifact Contact (Extended)
.... 8.39 Author Language
.... 8.40 Consultation Period
.... 8.41 First Publication Date
.... 8.42 Guideline Author Role
.... 8.43 Medical Subject
.... 8.44 Medical Subject Category
.... 8.45 Planned Completion Date
.... 8.46 Publication Date
.... 8.47 Recommendation Review Status
.... 8.48 Registration Date
.... 8.49 RelatesTo Classifier
.... 8.50 RelatesTo Label
.... 8.51 Section Coding
.... 8.52 Section Intended Audience
.... 8.53 Section Keyword
.... 8.54 Section Language
.... 8.55 Submission Date
.... 8.56 AGREE II Domains Value Set
.... 8.57 AMSTAR 2 Confidence Ratings Value Set
.... 8.58 AWMF Guideline Class
.... 8.59 AWMF Guideline Status
.... 8.60 Body System Conditions
.... 8.61 Care Level
.... 8.62 Care Stage
.... 8.63 Clinical Application Type
.... 8.64 Content Types
.... 8.65 Dissemination Website
.... 8.66 Encounter Type
.... 8.67 Guideline Author Role
.... 8.68 Guideline Contact Point VS
.... 8.69 Guideline Release Type
.... 8.70 Guideline Sections
.... 8.71 Intended Audience Value Set
.... 8.72 Level Of Consensus
.... 8.73 Medical Subject Categories
.... 8.74 OCEBM 2009 Levels of Evidence Value Set
.... 8.75 OCEBM 2011 Levels of Evidence Value Set
.... 8.76 PICO related terms
.... 8.77 Rating Acceptability
.... 8.78 Rating Benefits And Harms
.... 8.79 Rating Certainty Of Evidence
.... 8.80 Rating Concern Degree
.... 8.81 Rating Equity
.... 8.82 Rating Feasibility
.... 8.83 Rating Preference And Values
.... 8.84 Rating Resources
.... 8.85 Recommendation Direction
.... 8.86 Recommendation Review Status Value Set
.... 8.87 Recommendation Strength (AWMF) ValueSet
.... 8.88 Recommendation Synthesis Type
.... 8.89 Recommendation Tags
.... 8.90 Remark Type
.... 8.91 RoB2 Overall Judgment ValueSet
.... 8.92 ROBIS Judgment of Risk of Bias Value Set
.... 8.93 ROBIS Risk of Bias Domains Value Set
.... 8.94 SIGN Grade of Recommendation Value Set
.... 8.95 SIGN Level of Evidence Value Set
.... 8.96 Target Patient Group
.... 8.97 AGREE II Domains
.... 8.98 AMSTAR 2 Overall Confidence Ratings
.... 8.99 awmf
.... 8.100 AWMF Guideline Class
.... 8.101 AWMF Guideline Status
.... 8.102 Body System Conditions
.... 8.103 Care Setting
.... 8.104 Clinical Application Type
.... 8.105 Contact Point
.... 8.106 Evidence To Decision Certainty Rating
.... 8.107 Evidence To Decision Certainty type
.... 8.108 Guideline Author Role
.... 8.109 Guideline Release Type
.... 8.110 Guideline Sections
.... 8.111 Intended Audience Code System
.... 8.112 Level of Consensus
.... 8.113 Medical Subject Categories
.... 8.114 OCEBM 2009 Levels of Evidence
.... 8.115 OCEBM 2011 Levels of Evidence
.... 8.116 PICO Related Terms
.... 8.117 Recommendation Direction
.... 8.118 Recommendation Review Status Code System
.... 8.119 Recommendation Strength (AWMF)
.... 8.120 Recommendation Synthesis Type
.... 8.121 Recommendation Tags
.... 8.122 Related Artifact Types
.... 8.123 Remark Type
.... 8.124 RoB2 Overall Judgment
.... 8.125 ROBIS Judgment of Risk of Bias
.... 8.126 ROBIS Risk of Bias Domains
.... 8.127 SIGN Grade of Recommendation
.... 8.128 SIGN Level of Evidence
.... 8.129 Target Patient Group
.... 8.130 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)
.... 8.131 AWMF Guideline Record S3 Example
.... 8.132 AWMF Guideline S1 Example
.... 8.133 AWMF Guideline S2e Example
.... 8.134 AWMF Guideline S2k Example
.... 8.135 AWMF Member Organization Example
.... 8.136 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Antibiotic Days
.... 8.137 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Mortality
.... 8.138 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Time to Deescalation
.... 8.139 Certainty of Evidence Rating Ris of Bias for Cognitive Tests When Suspecting Dementia - Sensitivity
.... 8.140 Certainty of Evidence Rating Ris of Bias for Cognitive Tests When Suspecting Dementia - Specificity
.... 8.141 Citation Systematic Review
.... 8.142 Concept map from concepts from standardized vocabularies (that are not standard OMOP concepts) to Concept IDs of OMOP standard Concepts
.... 8.143 contributor0
.... 8.144 contributor1
.... 8.145 contributor2
.... 8.146 contributor3
.... 8.147 contributor4
.... 8.148 DGAI
.... 8.149 DGCH
.... 8.150 DGHM
.... 8.151 DGI
.... 8.152 DGIIN
.... 8.153 DGIM
.... 8.154 DGP
.... 8.155 DGPPN
.... 8.156 DRG
.... 8.157 DSG
.... 8.158 Evidence-Multiplex PCR Diagnostic-Antibiotic Days
.... 8.159 Evidence-Multiplex PCR Diagnostic-Mortality
.... 8.160 Evidence-Multiplex PCR Diagnostic-Time to Deescalation
.... 8.161 Foliensatz
.... 8.162 GfV
.... 8.163 Guideline Attachment Example
.... 8.164 Guideline Attachment Patient Version Example
.... 8.165 Guideline Author Example
.... 8.166 Guideline Author Role Example
.... 8.167 Guideline Example
.... 8.168 Guideline Registry Record Example
.... 8.169 Guideline with contributing author referencing Practitioner (fails invariant)
.... 8.170 Guideline with leading author referencing Organization (passes invariant)
.... 8.171 Guideline with leading author referencing Practitioner (fails invariant)
.... 8.172 HAP Diagnose
.... 8.173 HAP Diagnose - Empfehlung A
.... 8.174 HAP Diagnose - Empfehlung B
.... 8.175 Implementierungshilfe
.... 8.176 Jessica Rademacher
.... 8.177 Jessica Rademacher for DGP in the context of 020-013
.... 8.178 Kurzfassung
.... 8.179 Langfassung
.... 8.180 Leitlinienreport
.... 8.181 Medical Society Example
.... 8.182 Multiplex-PCR-Diagnostik
.... 8.183 Netzwerk chronisch pulmonale Aspergillose (CPAnet)
.... 8.184 Outcome Antibiotic Days
.... 8.185 Outcome Mortality
.... 8.186 Outcome Time to Deescalation
.... 8.187 Patienteninformation
.... 8.188 PEG
.... 8.189 PICO Comparator of Recommendation 17 from Guideline 038-013
.... 8.190 PICO Intervention of Recommendation 17 from Guideline 038-013
.... 8.191 PICO Outcome Sensitivity of Recommendation 17 from Guideline 038-013
.... 8.192 PICO Outcome Specificity of Recommendation 17 from Guideline 038-013
.... 8.193 PICO Population of Recommendation 17 from Guideline 038-013
.... 8.194 PICO Question of Recommendation 17 from Guideline 038-013
.... 8.195 Recommendation Example
.... 8.196 Recommendation-PlanDefinition-example
.... 8.197 RecommendationCognitiveTestsWhenSuspectingDementia-Justification
.... 8.198 RecommendationHAPDiagnosis-A-Justification
.... 8.199 RecommendationHAPDiagnosis-B-Justification
.... 8.200 RecommendationMultiplexPCRDiagnostic-Justification
.... 8.201 Robert Koch-Institut
.... 8.202 S3-Leitlinie Demenzen Living Guideline - Langfassung
.... 8.203 S3-Leitlinie Demenzen Living Guideline - Record
.... 8.204 S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
.... 8.205 S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
.... 8.206 Screening auf kognitive Beeinträchtigung
.... 8.207 Test: Author Both Leading and Contributing (Should Fail)
.... 8.208 Test: No Official Identifier (Should Fail)
.... 8.209 Test: No Official Identifier (Should Fail)
.... 8.210 Test: No Registrant Author (Should Fail)
.... 8.211 Test: Preliminary With Consultation Period (Should Pass)
.... 8.212 Test: Preliminary Without Consultation Period (Should Fail)
.... 8.213 Test: Registered With Planned Completion Date (Should Pass)
.... 8.214 Test: Registered Without Planned Completion Date (Should Fail)
.... 8.215 Test: Release Type If Registered (Should Pass)
.... 8.216 Test: Release Type No Tag (Should Fail)
.... 8.217 Test: Release Type Wrong Code (Should Fail)
.... 8.218 Test: Single Registrant Author (Should Pass)
.... 8.219 Test: Two Official Identifiers (Should Fail)
.... 8.220 Test: Two Official Identifiers (Should Fail)
.... 8.221 Test: Two Registrant Authors (Should Fail)
.... 8.222 Test: Version as Text (Should Fail)
.... 8.223 Test: Version as Text (Should Fail)
.... 8.224 Test: Version Major.Minor.Patch (Should Fail)
.... 8.225 Test: Version Major.Minor.Patch (Should Fail)
.... 8.226 Test: Version with Prefix (Should Fail)
.... 8.227 Test: Version with Prefix (Should Fail)